Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI

McMaster University

$17,976.00

Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH)

FY 2022-23

Summary
Our study (CoVasc-ICH) aims to improve the care of patients who survive stroke due to bleeding in the brain, known as "hemorrhagic stroke". Hemorrhagic strokes happen when weakened blood vessels rupture and cause bleeding in the brain. Patients with hemorrhagic stroke have a 1 in 10 risk each year of suffering 'major cardiovascular events' due to clotting (like a heart attack or stroke) or bleeding (like another brain bleed). A new treatment option is needed that can reduce the risk of clotting without increasing the risk of another bleed in these patients. Colchicine is a drug that has been used for more than 50 years in various other medical conditions. It is well tolerated and safe. Recently colchicine was found to reduce clotting by reducing inflammation, in a manner that does not increase bleeding. These properties make colchicine an attractive drug for patients with hemorrhagic stroke. CoVasc-ICH aims to test whether colchicine can reduce the risk of clotting without increasing the risk of re-bleeding after a hemorrhagic stroke. It will be a type of experiment known as a 'randomized controlled trial.' Randomized controlled trials are the most reliable tests of treatments. We will include 1400 patients with a hemorrhagic stroke occurring within 48 hours. These patients will be assigned at random, with a 50:50 chance of either receiving daily low-dose colchicine or placebo. We will follow them for an average of 2 years until enough events have occurred for us to be able to confidently detect whether using colchicine prevents major cardiovascular events compared to placebo. During this time patients will be monitored for bleeding and clotting outcomes. The number of these events in each group will be monitored closely by a separate panel of doctors to ensure the safety of patients in the study. The results of CoVasc-ICH will have the potential to substantially improve the health of the 250,000 people who survive a hemorrhagic stroke each year worldwide.
Program
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
485530
Name
Katsanos Aristeidis
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Team Grant : Intervention Trial in Inflammation for Chronic Conditions
Projecttitle
Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH)
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$17,976
Cihrequipment2
$0
Programname2
Team Gr.:Intervention Trial in Inflam. for Chronic Condition - General Pool LOI
Keyworddelim
Ageing; Atherosclerosis; Cerebral Small Vessel Disease; Cognitive Impairment; Hemorrhagic Stroke; Inflammation; Intracerebral Hemorrhage; Neuroinflammation; Prevention; Vascular Events
Abstract
Our study (CoVasc-ICH) aims to improve the care of patients who survive stroke due to bleeding in the brain, known as "hemorrhagic stroke". Hemorrhagic strokes happen when weakened blood vessels rupture and cause bleeding in the brain. Patients with hemorrhagic stroke have a 1 in 10 risk each year of suffering 'major cardiovascular events' due to clotting (like a heart attack or stroke) or bleeding (like another brain bleed). A new treatment option is needed that can reduce the risk of clotting without increasing the risk of another bleed in these patients. Colchicine is a drug that has been used for more than 50 years in various other medical conditions. It is well tolerated and safe. Recently colchicine was found to reduce clotting by reducing inflammation, in a manner that does not increase bleeding. These properties make colchicine an attractive drug for patients with hemorrhagic stroke. CoVasc-ICH aims to test whether colchicine can reduce the risk of clotting without increasing the risk of re-bleeding after a hemorrhagic stroke. It will be a type of experiment known as a 'randomized controlled trial.' Randomized controlled trials are the most reliable tests of treatments. We will include 1400 patients with a hemorrhagic stroke occurring within 48 hours. These patients will be assigned at random, with a 50:50 chance of either receiving daily low-dose colchicine or placebo. We will follow them for an average of 2 years until enough events have occurred for us to be able to confidently detect whether using colchicine prevents major cardiovascular events compared to placebo. During this time patients will be monitored for bleeding and clotting outcomes. The number of these events in each group will be monitored closely by a separate panel of doctors to ensure the safety of patients in the study. The results of CoVasc-ICH will have the potential to substantially improve the health of the 250,000 people who survive a hemorrhagic stroke each year worldwide.
Competitiondate
202303
Approvedterm2
1 yr 0 mth
Pinamesdelim
Katsanos, Aristeidis; Shoamanesh, Ashkan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,976~ $0~